ReviewFrontiers in bioengineering and biotechnology2026
Role of Notch signaling pathway in joint homeostasis and osteoarthritis.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Notch signaling pathway is pivotal in joint homeostasis and the pathogenesis of osteoarthritis (OA). Under physiological conditions, transient or physiological Notch signaling maintains cartilage matrix synthesis to preserve joint function. Under pathological conditions, persistent or excessive activation of Notch signaling suppresses the expression of chondrogenic genes and induces the production of catabolic factors, thereby driving OA progression. From a cellular perspective, the Notch signaling pathway exerts crucial regulatory role in the functions of various resident cell types within the joint. For instance, it regulates the differentiation and maturation of chondrocytes, influences the chondrogenic differentiation process of mesenchymal stem cells (MSCs), and modulates the phenotype of fibroblast-like synoviocytes (FLSs). At the level of the extracellular cartilage microenvironment, the Notch signaling pathway participates in extracellular matrix (ECM) homeostasis imbalance and inflammatory factor activation in OA by regulating the expression of downstream genes. Furthermore, Notch controls chondrocyte hypertrophic degeneration through extensive molecular crosstalk with the TGF-β/BMP, Wnt/β-catenin, NF-κB, and Hippo-YAP pathways. Beyond cartilage, Notch plays a crucial role in promoting neurovascular invasion at the osteochondral junction and abnormal subchondral bone remodeling, which directly contributes to joint pain and structural failure. Many Notch-targeted approaches, such as pharmacological inhibitors, RNA-based therapies, and molecular interventions targeting ligands and downstream effectors, have been investigated because existing treatments are unable to stop the progression of OA. Simultaneously, stem cell-based approaches use precise Notch modulation to improve cartilage repair and chondrogenic differentiation. However, systemic administration of small-molecule inhibitors raises concerns about off-target effects and delivery inefficiency in avascular cartilage, while conventional stem cell injections frequently encounter problems like phenotypic instability and limited durability. In conclusion, in-depth studies on the Notch signaling pathway in OA not only clarify the pathogenesis of OA but also lay a theoretical and experimental foundation for the development of innovative therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.